Akums Drugs and Pharmaceuticals · NSE: AKUMS · BSE: 544222
Q2 FY25 results · Jul–Sep 2024
Akums Drugs and Pharmaceuticals reported revenue from operations of ₹1,033.09 crore and net profit of ₹66.65 crore for Q2 FY25 (Jul–Sep 2024), on a consolidated basis.
| Item | Q2 FY25 | Q2 FY24 | YoY | Q1 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 1,033.09 | — | — | 1,019.11 | +1.4% |
| Other income | 13.47 | — | — | 6.55 | +105.8% |
| Total income | 1,046.56 | — | — | 1,025.66 | +2.0% |
| Profit before tax | 91.59 | — | — | 87.48 | +4.7% |
| Net profit for the period | 66.65 | — | — | 61.21 | +8.9% |
| Attributable to shareholders of the company | 65.21 | — | — | 60.17 | +8.4% |
| EPS, basic (₹) | 4.37 | — | — | 4.21 | +3.8% |
| Net margin (%) | 6.5 | — | 6.0 |
| Item | Q2 FY25 | Q2 FY24 | YoY | Q1 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 328.35 | — | — | 317.27 | +3.5% |
| Other income | 32.12 | — | — | 26.18 | +22.7% |
| Total income | 360.47 | — | — | 343.45 | +5.0% |
| Profit before tax | 61.62 | — | — | 54.27 | +13.5% |
| Net profit for the period | 50.37 | — | — | 41.88 | +20.3% |
| EPS, basic (₹) | 3.38 | — | — | 2.93 | +15.4% |
| Net margin (%) | 15.3 | — | 13.2 |
Consolidated
- Filed with BSE
- 09 Nov 2024, 17:58 IST
- Board meeting
- 09 Nov 2024
- Period
- 01 Jul 2024 to 30 Sep 2024
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 09 Nov 2024, 17:58 IST
- Board meeting
- 09 Nov 2024
- Period
- 01 Jul 2024 to 30 Sep 2024
- Review status
- Unaudited
- Source
- XBRL filing on BSE